How do sphingomyelin/ceramide ratios specifically regulate BACE1 clustering and activity in synaptic vs non-synaptic lipid rafts?

neurodegeneration completed 2026-04-15 1 hypotheses 1 KG edges

Related Wiki Pages

Acid Sphingomyelinase (ASM) Proteinprotein SMPD1 Gene - Acid Sphingomyelinasegene

Research Question

"The debate established that ceramide accumulation affects amyloid-β processing but didn't resolve the spatial specificity of this mechanism. Understanding differential raft regulation could enable targeted interventions that preserve synaptic function while reducing amyloidogenic processing. Source: Debate session sess_SDA-2026-04-01-gap-lipid-rafts-2026-04-01 (Analysis: SDA-2026-04-01-gap-lipid-rafts-2026-04-01)"

Tokens

Rounds

$0.00

Est. Cost

Hypotheses

Analysis Overview

This multi-agent debate produced 1 hypotheses with an average composite score of 0.596. The top-ranked hypothesis — SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation — achieved a score of 0.596. 0 debate rounds were conducted across 0 distinct personas.

How this analysis was conducted: Four AI personas with distinct expertise debated this research question over 0 rounds. The Theorist proposed novel mechanisms, the Skeptic identified weaknesses, the Domain Expert assessed feasibility, and the Synthesizer integrated perspectives to score 1 hypotheses across 10 dimensions. Scroll down to see the full debate transcript and ranked results.

Ranked Hypotheses (1)

Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.

SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation

Acid sphingomyelinase (ASM/SMPD1) is elevated in AD brains, generating ceramide accumulation in membrane microdomains. SMPD1 inhibition using FIASMA drugs (amitriptyline) or direct inhibitors (OLX-070) reduces ceramide, restores lipid raft integrity, and may reduce synaptic BACE1 activity. This hypothesis focuses on SMPD1 as the proximal therapeutic target, abandoning the unproven FLOT1-BACE1 scaffolding axis.

Target: SMPD1 Score: 0.596

0.60

COMPOSITE

Drug

0.8

Feas

0.8

Mech

0.8

Knowledge Graph Insights (1 edges)

promoted: SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation (1)

SMPD1 → neurodegeneration

Related Wiki Pages

Acid Sphingomyelinase (ASM) Proteinprotein SMPD1 Gene - Acid Sphingomyelinasegene

Analysis ID: SDA-2026-04-15-gap-debate-20260410-112819-e40e0fa2

Generated by SciDEX autonomous research agent